Assyro AI

FDA Orange Book · active-ingredient family

Droperidol

Droperidol is approved as 1 brand and 18 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:INAPSINE · NDA 016796

1

Brand (NDA)

18

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
INAPSINERLDRISINGNDA 016796Approved Prior to Jan 1, 1982

Generic (ANDA) products (18)

ProductApplicantApplicationTEApproved
DROPERIDOLHIKMAANDA 208197APDec 14, 2017
DROPERIDOLHOSPIRAANDA 072272Aug 31, 1995
DROPERIDOLWATSON LABSANDA 073520Nov 27, 1991
DROPERIDOLWATSON LABSANDA 073521Nov 27, 1991
DROPERIDOLWATSON LABSANDA 073523Nov 27, 1991
DROPERIDOLAM REGENTANDA 072123APOct 24, 1988
DROPERIDOLLUITPOLDANDA 072335Oct 24, 1988
DROPERIDOLASTRAZENECAANDA 072018Oct 20, 1988
DROPERIDOLIGI LABS INCANDA 072019Oct 19, 1988
DROPERIDOLIGI LABS INCANDA 072020Oct 19, 1988
DROPERIDOLIGI LABS INCANDA 072021Oct 19, 1988
DROPERIDOLSMITH AND NEPHEWANDA 071750Sep 06, 1988
DROPERIDOLSOLOPAKANDA 071754Sep 06, 1988
DROPERIDOLSOLOPAKANDA 071755Sep 06, 1988
DROPERIDOLHOSPIRAANDA 071645Apr 07, 1988
DROPERIDOLHOSPIRAANDA 071981Feb 29, 1988
DROPERIDOLABRAXIS PHARMANDA 070992Nov 17, 1986
DROPERIDOLABRAXIS PHARMANDA 070993Nov 17, 1986

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Droperidol — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.